Pembrolizumab plus lenvatinib with belzutifan or quavonlimab as first-line therapy for advanced renal-cell carcinoma: randomized open-label phase 3 LITESPARK-012 study.


Rini B. I., Choueiri T. K., Voss M. H., Burotto M., Oldenburg J., Gurney H. P., ...Daha Fazla

Annals of oncology : official journal of the European Society for Medical Oncology, 2026 (SCI-Expanded, Scopus)